Dana Blankenhorn

Dana Blankenhorn

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

DJT Stock: 21 Million Reasons Trump Media Shares Are Struggling to Stay Afloat

DJT stock could rise near the end of its lock-up period, allowing Trump to exercise his warrants at a profit.

Why I Bought the Dip in Apple Stock – and You Should, Too

Apple stock will control its AI supply chain, fend off the government regulators, and push the envelope of what computers can do.

PLL Stock Alert: Piedmont Lithium Surges on North Carolina Mine Permit

Piedmont hopes to get its mining operations rolling before new supplies can come on from Nevada or California.

Tesla Layoffs 2024: What to Know About the Latest TSLA Job Cuts

Tesla copied Detroit's automakers with the CyberTruck, yet it's still worth 10 times more. For how long, though?

The Fall of China’s Tech Giant: How Alibaba’s Woes Expose the Perils of Xi’s Crackdown

Alibaba can’t deliver innovation because Xi Jinping won’t let it.

JPM Stock Falls as CEO Jamie Dimon Sounds Alarm Bells on Inflation

CEO Jamie Dimon's shareholder letter reminded investors that there is economic uncertainty ahead, and the market sold off.

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Why You Should Wait for Some Dip Before Biting Into Apple Stock

You buy on weakness and sell into strength. Apple stock is weak right now.

What Is Going on With Jaguar Health (JAGX) Stock Today?

A fifth reverse split may be coming to JAGX stock. Jaguar Health is seeking customers for its Crofelemer anti-diarrhea medicine.

XPEV Stock Alert: XPeng Charges Up on Move Into Hong Kong, Macau

XPeng and other Chinese EV makers are just starting to ratchet up exports, shaking up the entire industry in the process.